CLINICAL TRIALS PROFILE FOR ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE
✉ Email this page to a colleague
All Clinical Trials for ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01699022 ↗ | Pharmacokinetic and Pharmacodynamic Study of Cyclofem | Completed | Sun Pharmaceutical Industries Limited | Phase 1/Phase 2 | 2010-06-01 | Cyclofem® is a monthly injectable contraceptive containing 25 mg of medroxyprogesterone acetate (MPA) and 5 mg of estradiol cypionate (E2C), a long-acting ester of estradiol. The current study will assess the steady-state pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate (MPA) and estradiol (E2) after administration of Cyclofem® and will provide critical information to determine similar bioavailability of Cyclofem to Lunelle in women residing in the United States of America. |
| NCT03443089 ↗ | Comparative Bioavailability of Two Injectable Suspension Formulations of Medroxyprogesterone Acetate+Estradiol Cypionate | Completed | Biolab Sanus Farmaceutica | Phase 1 | 2017-03-31 | This clinical trial evaluated the comparative bioavailability of two injectable suspension formulations of medroxyprogesterone acetate + estradiol cypionate, a test (Depomês®, 25 mg/mL medroxyprogesterone acetate + 5 mg/mL estradiol cypionate, Biolab Sanus Farmacêutica Ltda.) and a reference formulation (Cyclofemina®, 25 mg/0.5 mL medroxyprogesterone acetate + 5 mg/0.5 mL estradiol cypionate, Millet Roux Ltda.) in healthy female volunteers after a single intramuscular dose administration. In addition, this study also evaluated the safety and tolerability of these drugs. |
| NCT03443089 ↗ | Comparative Bioavailability of Two Injectable Suspension Formulations of Medroxyprogesterone Acetate+Estradiol Cypionate | Completed | Galeno Desenvolvimento de Pesquisas Clínicas | Phase 1 | 2017-03-31 | This clinical trial evaluated the comparative bioavailability of two injectable suspension formulations of medroxyprogesterone acetate + estradiol cypionate, a test (Depomês®, 25 mg/mL medroxyprogesterone acetate + 5 mg/mL estradiol cypionate, Biolab Sanus Farmacêutica Ltda.) and a reference formulation (Cyclofemina®, 25 mg/0.5 mL medroxyprogesterone acetate + 5 mg/0.5 mL estradiol cypionate, Millet Roux Ltda.) in healthy female volunteers after a single intramuscular dose administration. In addition, this study also evaluated the safety and tolerability of these drugs. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE
Condition Name
Clinical Trial Locations for ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE
Trials by Country
Clinical Trial Progress for ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE
Clinical Trial Phase
Clinical Trial Sponsors for ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE
Sponsor Name
